GrottaJCBurginWSEl MitwalliA. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol2001; 58:2009–13.
2.
GreenAROdergrenTAshwoodA: Animal models of stroke: do they have value for discovering neuroprotective agents?Trends Pharmacol Sci2003; 24:402–8.
3.
OvbiageleBKidwellCSStarkmanS. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Cardiovasc Med2003; 5:441–9.
4.
WahlgrenNGAhmedN: Neuroprotection in cerebral ischaemia: facts and fancies – the need for new approaches. Cerebrovasc Dis2004; 17:153.
5.
BlondeauNHeurteauxC: Cerebral tolerance: a new challenge to identify targets for cerebral protection. Med Sci (Paris)2004; 20:1109–14.
6.
GladstoneDJBlackSEHakimAM: Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke2002; 33:2123–36.
7.
FisherM: Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke2003; 34:1539–46.
8.
MarshallJWCummingsRMBowesLJ. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke2003; 34:2228–33.
9.
WangCXShuaibA: NXY-059: A neuroprotective agent in acute stroke. Int J Clin Pract2004.
10.
LeesKRBarerDFordGA. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke2003; 34:482–7.
11.
Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke1999; 30:2752–8.
12.
Stroke Therapy Academic Industry Roundtable II. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke2001; 32:1598–606.
